Seaport Therapeutics’ (SPTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Seaport Therapeutics (NASDAQ:SPTX) in a research report report published on Tuesday, MarketBeat Ratings reports. They currently have a $50.00 price target on the stock. HC Wainwright also issued estimates for Seaport Therapeutics’ FY2026 earnings at ($4.09) EPS, Q1 2027 earnings at ($0.62) EPS, Q3 2027 earnings at ($0.67) EPS and FY2027 earnings at ($2.62) EPS.

Several other brokerages have also recently commented on SPTX. Zacks Research raised shares of Seaport Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. UBS Group lowered Seaport Therapeutics to a “sell” rating in a research report on Tuesday, June 9th. JPMorgan Chase & Co. initiated coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued an “overweight” rating and a $42.00 price objective on the stock. Leerink Partners began coverage on Seaport Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, Seaport Research Partners set a $50.00 target price on Seaport Therapeutics in a report on Wednesday, July 15th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $38.40.

Seaport Therapeutics Price Performance

Shares of SPTX opened at $23.09 on Tuesday. The firm has a market capitalization of $1.24 billion and a PE ratio of -2.23. Seaport Therapeutics has a 1 year low of $14.85 and a 1 year high of $23.34. The stock’s 50-day simple moving average is $19.60.

Seaport Therapeutics (NASDAQ:SPTX) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07). On average, equities research analysts forecast that Seaport Therapeutics will post -4.33 EPS for the current year.

Insiders Place Their Bets

In other news, Director Robert J. Hombach bought 13,000 shares of Seaport Therapeutics stock in a transaction that occurred on Monday, June 22nd. The shares were purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the completion of the acquisition, the director directly owned 13,000 shares in the company, valued at $235,820. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

About Seaport Therapeutics

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.